Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Blum

Showing results (51-60 of 290) with videos related to

Pageof 29
Sort By:
Current Pharmaceutical Design|June 10, 2008
A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's diseasePatrizia Popoli, David Blum, Maria Rosaria Domenici, et al.
Advances in Experimental Medicine and Biology|February 26, 2020
Tau, Diabetes and InsulinMaud Gratuze, Aurélie Joly-Amado, Luc Buee, et al.
Epilepsia|February 18, 2015
Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North AmericaMichael R Sperling, Jay Harvey, Todd Grinnell, et al.
Palliative Medicine Reports|January 22, 2024
Outpatient Palliative Care Service Involvement: A Five-Year Experience from a Tertiary Hospital in SwitzerlandDorothea Rebekka Birkner, Markus Schettle, Markus Feuz, et al.
Neurobiology of Disease|September 25, 2002
Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's diseaseDavid Blum, Marie-Christine Galas, David Gall, et al.
Neurobiology of Aging|October 27, 2006
Citicoline is not protective in experimental models of Huntington's diseaseStéphane Mievis, Marc Levivier, Gilbert Vassart, et al.
Comprehensive Psychoneuroendocrinology|March 14, 2024
The Psychoneuroimmunological Model of Moral Distress and Health in Healthcare Workers: Toward Individual and System-Level SolutionsAnnina Seiler, Aimee Milliken, Richard E Leiter, et al.
The Lancet. Neurology|July 10, 2003
Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeuticsDavid Blum, Raphaël Hourez, Marie-Christine Galas, et al.
The Journal of Pain|May 5, 2009
A randomized, double-blind, placebo-controlled trial of a selective COX-2 inhibitor, GW406381, in patients with postherpetic neuralgiaSteve Shackelford, Richard Rauck, Steve Quessy, et al.
Neuroscience Letters|November 20, 2003
Minocycline-induced activation of tetracycline-responsive promoterAbdelwahed Chtarto, Liliane Tenenbaum, Thierry Velu, et al.
Pageof 29

Showing results (51-60 of 290) with videos related to

Sort By:
Pageof 29
Current Pharmaceutical Design|June 10, 2008
A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's diseasePatrizia Popoli, David Blum, Maria Rosaria Domenici, et al.
Advances in Experimental Medicine and Biology|February 26, 2020
Tau, Diabetes and InsulinMaud Gratuze, Aurélie Joly-Amado, Luc Buee, et al.
Epilepsia|February 18, 2015
Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North AmericaMichael R Sperling, Jay Harvey, Todd Grinnell, et al.
Palliative Medicine Reports|January 22, 2024
Outpatient Palliative Care Service Involvement: A Five-Year Experience from a Tertiary Hospital in SwitzerlandDorothea Rebekka Birkner, Markus Schettle, Markus Feuz, et al.
Neurobiology of Disease|September 25, 2002
Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's diseaseDavid Blum, Marie-Christine Galas, David Gall, et al.
Neurobiology of Aging|October 27, 2006
Citicoline is not protective in experimental models of Huntington's diseaseStéphane Mievis, Marc Levivier, Gilbert Vassart, et al.
Comprehensive Psychoneuroendocrinology|March 14, 2024
The Psychoneuroimmunological Model of Moral Distress and Health in Healthcare Workers: Toward Individual and System-Level SolutionsAnnina Seiler, Aimee Milliken, Richard E Leiter, et al.
The Lancet. Neurology|July 10, 2003
Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeuticsDavid Blum, Raphaël Hourez, Marie-Christine Galas, et al.
The Journal of Pain|May 5, 2009
A randomized, double-blind, placebo-controlled trial of a selective COX-2 inhibitor, GW406381, in patients with postherpetic neuralgiaSteve Shackelford, Richard Rauck, Steve Quessy, et al.
Neuroscience Letters|November 20, 2003
Minocycline-induced activation of tetracycline-responsive promoterAbdelwahed Chtarto, Liliane Tenenbaum, Thierry Velu, et al.
Pageof 29